Compare Peptides Side by Side

Put any two or three of the 79 library entries next to each other on compound class, molecular weight, half-life, origin, mechanism and studied research areas — the attributes that actually distinguish one compound from another.

BPC-157 vs TB-500 Semaglutide vs Tirzepatide vs Retatrutide Sermorelin vs CJC-1295 vs Ipamorelin Selank vs Semax GHK-Cu vs AHK-Cu Ipamorelin vs Hexarelin vs GHRP-2

Compound A Compound B Compound C optional

Side-by-side comparison of BPC-157, TB-500 on compound class, molecular weight, half-life, origin, mechanism and studied research areas.
Attribute	BPC-157	TB-500
Compound class	Synthetic pentadecapeptide	Actin-binding peptide fragment
Research category	Healing & Recovery	Healing & Recovery
Length (amino acids)	15	7
Molecular weight	1419.5 Da	~4921 Da (full-length thymosin beta-4); ~889 Da for the Ac-LKKTETQ fragment form
Half-life	<30 minutes (elimination, reported in rats/dogs)	~2-3 hours (elimination); tissue effects reported to persist for days
Origin	BPC-157 is a synthetic peptide whose sequence corresponds to a partial fragment of human body protection compound (BPC), a protein reported to be present in gastric juice. It does not occur naturally as an isolated peptide and is produced synthetically for research.	TB-500 is a synthetic peptide commonly described as corresponding to the actin-binding domain (a short fragment, often the LKKTETQ region) of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in actin regulation. TB-500 is produced synthetically and is not identical to full-length Thymosin Beta-4.
Mechanism	In animal and in-vitro studies, BPC-157 has been associated with promotion of angiogenesis and modulation of growth-factor signaling pathways, including effects reported on the VEGFR2 pathway and nitric oxide systems. Researchers have also described interactions with the FAK-paxillin pathway and effects on fibroblast and tendon-cell migration. These mechanisms are characterized primarily in rodent models and cell culture and have not been established in controlled human trials.	Thymosin Beta-4 and its actin-binding fragment are studied for their ability to sequester G-actin and influence actin polymerization, which relates to cell migration. In preclinical models, this activity has been linked to cell migration, angiogenesis and tissue-repair processes. These mechanisms are drawn largely from animal and cell-culture research and are not established in controlled human trials for TB-500 itself.
Research areas	Tendon, ligament and muscle healing (animal models) Gastrointestinal mucosal protection and ulcer healing (rodent studies) Angiogenesis and wound healing (preclinical) Nerve and bone injury repair (animal models) Modulation of NSAID-related gastrointestinal injury (rodent studies)	Cell migration and actin cytoskeleton dynamics (in-vitro) Wound healing and tissue repair (animal models) Angiogenesis (preclinical) Cardiac and corneal repair (Thymosin Beta-4 research) Inflammation modulation (preclinical)
What sets it apart	Unlike copper-binding cosmetic tripeptides or the actin-modulating TB-500, BPC-157 is a longer synthetic peptide studied primarily for connective-tissue and gastrointestinal repair endpoints in animals.	TB-500 is defined by its actin-binding fragment identity, distinguishing it from BPC-157's growth-factor/angiogenesis focus and from copper tripeptides used cosmetically.

Every compound you can compare

All 79 library entries. The pickers above hold the same list; these are direct links to each full entry.

Every published comparison

118 written head-to-head pages, one for each pairing the library already documents as co-studied. Each sets the two compounds against each other on class, mass, half-life, origin, mechanism and shared research areas.

Reading a peptide comparison

Compound class is the most useful first filter — a GHRH analog and a ghrelin-receptor agonist both sit in growth-axis research, but they act on different receptors and are studied for different reasons. Two compounds in the same category are not interchangeable.

Half-life determines how a compound behaves over time in a study design, and it varies enormously: some research peptides clear in minutes, others persist for days. It is the single largest driver of protocol differences between otherwise similar compounds.

Molecular weight and length indicate whether a compound is a short synthetic fragment or a larger protein-like molecule, which in turn affects stability, storage, and how it is handled in the lab.

Origin distinguishes naturally occurring sequences from synthetic analogs designed to modify half-life, receptor selectivity, or stability relative to the parent molecule.

Deeper comparisons

For narrative comparisons with the underlying research context rather than a specification table:

BPC-157 vs TB-500 — the two most commonly stacked tissue-repair peptides.
Sermorelin vs CJC-1295 — two GHRH analogs with very different half-lives.
Selank vs Semax — two short synthetic peptides in nootropic research.
GLP-1 family comparison — mono-, dual- and triple-agonist compounds.